BioIQ, an analytics-driven population health and testing platform company for top U.S. employers, health plans, and government agencies, has been approved by the Japanese government to facilitate COVID-19 testing for…
Read More
BioIQ, an analytics-driven population health and testing platform company for top employers, health plans, and government agencies, was recently announced as a 2021 Georgia Fast 40 program honoree by the Atlanta…
Read More
BioIQ, an analytics-driven population health and testing platform company for top employers, health plans, and government agencies, announces a partnership with MLU Services, Inc., a trusted FEMA partner and leading…
Read More
BioIQ, an analytics-driven population health and testing platform company, introduces a first of its kind, end-to-end COVID-19 mitigation solution for employers, health plans, and government agencies. Built on the same…
Read More
BioIQ, an analytics-driven population health and testing platform company for top employers and health plans, announces the launch of an integrated telehealth offering procured through the acquisition of BlipIQ, a…
Read More
Ernst & Young LLP (EY US) today announced that Justin Bellante of BioIQ was named an Entrepreneur Of The Year(®) 2020 Southeast Award finalist. Now in its 34th year, the Entrepreneur Of The Year program honors entrepreneurial business leaders whose ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses that transform our world. Bellante was selected as one of 30 finalists from a competitive pool of nominations by a panel of independent judges.
Read More
BioIQ, a healthcare engagement and clinical adherence technology platform company, has partnered with Cresa and Ogletree Deakins to help employers navigate the many practical and legal issues to consider when crafting a workplace COVID-19 testing and return-to-work strategy. The BioIQ return-to-work ecosystem is designed to move employers up the learning curve quickly and expedite efforts to reopen the US economy.
Read More
BioIQ, a healthcare engagement and clinical adherence technology platform company, announces the availability of an at-home RT-PCR COVID-19 testing solution with fully integrated telehealth support. The test is being offered in partnership with P23 Labs, one of the first laboratories to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for home saliva collection in conjunction with telehealth oversight. The partnership enables BioIQ to connect employees, health plan members, and individuals with COVID-19 diagnostic testing under the virtual supervision of a clinician.
Read More
BioIQ, a healthcare engagement and clinical adherence technology platform company, and Matrix Medical Network, a clinical leader in supporting the needs of at-risk populations, announce the availability of a COVID-19 testing, testing protocol, assessment and monitoring program for US employers as the country lays out plans to bring employees back to work. With clinical oversight provided by Matrix’s national array of locally based providers paired with BioIQ’s comprehensive technology and testing platform, the two companies provide a robust solution that is designed to protect workers as the US readies for its first steps in re-opening the country.
Read More
BioIQ, a healthcare engagement and clinical adherence technology platform company, announces the addition of antibody testing to the company’s innovative COVID-19 population health solutions, including saliva RT-PCR diagnostic testing, for health plans, employers and government agencies. The recently added enzyme-linked immunosorbent assay (ELISA) test is the preferred standard in antibody testing and uses a blood or serum sample to determine whether an immunoglobulin (IgG/IgM) antibody is present in the test subject.
Read More